OncoPrecision

Engineering first-in-class ADCs and bispecifics – powered by patient-derived biology and AI – for hard-to-treat cancers.

[OncoPrecision @OncoPrecision1]

OncoPrecision is heading to #BIO2026 🌴

Our CEO, @TarekAliZaki, and Fractional CMO, Dr. Han Myint, will be attending the BIO International Convention, June 22–25 in San Diego, CA and are available for partnering meetings.

We're open to explore strategic collaborations across our platform and pipeline that advance our mission.

If you'd like to connect, please reach out 📩

[OncoPrecision @OncoPrecision1]

We're excited to share that our new website is live 🌅

Our mission is to develop first-in-class antibody-drug conjugates (ADCs) and bispecific antibodies for cancers where patients still have too few options. Our lead program, ONC001, is a CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages at the root of disease.

Visit us at https://t.co/A2gNgvPcpE to learn more about our science, our team, and our commitment to patients.

[Consulado General Argentino en Nueva York @ARGenNewYork]

Great to host an inspiring conversation with 🇦🇷 founders building in the U.S.!

Thanks @nachomarchionna, @JuanMBarrero, @MatiasRecchia, @TarekAliZaki & all participants for a dynamic exchange on innovation, startups & global growth.

Argentina connecting talent with opportunity.

[OncoPrecision @OncoPrecision1]

📢 Poster Presentation at #AACR26

We are pleased to share that data from ONC001, our first-in-class CD64-targeting antibody-drug conjugate (ADC), will be presented at the AACR Annual Meeting.

🔗 https://t.co/jYi8gDdsgm

[OncoPrecision @OncoPrecision1]

We’re pleased to share that our Co-Founder & CSO, @Gastonsoria, will be speaking at the 4th Annual ADC Linker & Conjugation Summit this July.

https://t.co/m64IGctYPs

[OncoPrecision @OncoPrecision1]

Please join us in congratulating Dr. Constanza Marin on her promotion to Staff Scientist 👩‍🔬🥳🧡

[OncoPrecision @OncoPrecision1]

📢 Oral Presentation at #ASH25

We are pleased to share that data from ONC001, our first-in-class CD64-targeting ADC, will be presented by our Co-Founder & Chief Scientific Officer, Dr. Gastón Soria, at the 67th ASH Annual Meeting and Exposition.

🔗: https://t.co/UEK99rjTvR

[OncoPrecision @OncoPrecision1]

October is hashtag#BreastCancerAwarenessMonth — a reminder of courage, resilience, and the power of science to bring hope 🎀🎀

This month, we’re shining a light on the importance of regular screening, early detection, and continued innovation in the search for new treatments.

[OncoPrecision @OncoPrecision1]

Blood cancers affect over 1.2 million people worldwide each year. This #BloodCancerAwarenessMonth, we are reminded of our commitment to raise awareness, support those impacted, and continue to push the boundaries of science so that every patient has a better tomorrow 🩸🧡

[OncoPrecision @OncoPrecision1]

OncoPrecision is heading to #BIO2025!

We look forward to engaging with partners, industry leaders, and innovators to exchange ideas, explore strategic collaborations, and advance patient-centric drug discovery efforts for novel cancer therapies.

[OncoPrecision @OncoPrecision1]

Please join us in congratulating our recently promoted Onconauts! 🎉🧡

[OncoPrecision @OncoPrecision1]

On this hashtag#WorldCancerDay we stand united with patients, their families, and all lives that are touched by cancer, as we strive to advance much-needed transformative therapies 🧡

[OncoPrecision @OncoPrecision1]

Happy Holidays from the OncoPrecision Team!

[OncoPrecision @OncoPrecision1]

Our CEO, @TarekAliZaki, will be participating in a panel discussion on Leveraging the Global Landscape: New Pathways and Geographies in Drug Development on January 15th hosted by @SOSV's @indbio and LOTTE Ventures U.S.

https://t.co/owlHKfX7aD

[OncoPrecision @OncoPrecision1]

Some of this year’s #ASH24 highlights pictured: catching up with our dear Advisors (Dr. @DrGwenNichols, Chief Medical Officer of @LLSusa at their stand and Dr. Jorge Solimano, VP and Head of Hematology of CEMIC over lunch), our annual picture with the ASH sign, and a bit of fun.

[Tarek Ali Zaki @TarekAliZaki]

That’s a wrap! #ASH24

[Solu Therapeutics @Solu_Tx]

This weekend, we’re presenting preclinical data from our #CMML & #AML programs at #ASH24 in San Diego. We’re proud to collaborate with experts from @MayoClinic, @MDAndersonNews, @DiscLS, and @OncoPrecision1. Read about our accepted abstracts: https://t.co/Xwhakf6evn

[OncoPrecision @OncoPrecision1]

We’re thrilled to welcome Dr. Stefan Oschmann to our Advisory Board.

Dr. Oschmann served as Chairman & CEO of Merck KGaA from 2016 to 2021, successfully leading the company through a period of transformation and growth.

https://t.co/dxN8Z0e2DK

[OncoPrecision @OncoPrecision1]

Last Thursday, our Team participated in @LLSusa Light the Night event in Manhattan's South Street Seaport. It was a powerful reminder of the importance of our work as we walked alongside an inspiring community of patients, survivors, and their loved ones 🧡🏮

[OncoPrecision @OncoPrecision1]

Our Team wore pink for the #InternationalDayAgainstBreastCancer to raise awareness about breast cancer and promote early detection, diagnosis, and treatment 🩷🎀